DK2370441T3 - Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister - Google Patents

Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister

Info

Publication number
DK2370441T3
DK2370441T3 DK09752380.7T DK09752380T DK2370441T3 DK 2370441 T3 DK2370441 T3 DK 2370441T3 DK 09752380 T DK09752380 T DK 09752380T DK 2370441 T3 DK2370441 T3 DK 2370441T3
Authority
DK
Denmark
Prior art keywords
dihydrotetraazabenzoazulenes
arylcyclohexylethers
vasopressin
receptor antagonists
antagonists
Prior art date
Application number
DK09752380.7T
Other languages
English (en)
Inventor
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2370441T3 publication Critical patent/DK2370441T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK09752380.7T 2008-11-28 2009-11-18 Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister DK2370441T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170188 2008-11-28
PCT/EP2009/065354 WO2010060836A1 (en) 2008-11-28 2009-11-18 Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists

Publications (1)

Publication Number Publication Date
DK2370441T3 true DK2370441T3 (da) 2013-10-21

Family

ID=41382009

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09752380.7T DK2370441T3 (da) 2008-11-28 2009-11-18 Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister

Country Status (31)

Country Link
US (2) US8227458B2 (da)
EP (1) EP2370441B1 (da)
JP (1) JP5452608B2 (da)
KR (1) KR101359742B1 (da)
CN (1) CN102227428B (da)
AR (2) AR074409A1 (da)
AU (1) AU2009319123B2 (da)
BR (1) BRPI0922303B1 (da)
CA (1) CA2743976C (da)
CO (1) CO6341478A2 (da)
CR (1) CR20110220A (da)
CY (1) CY1115435T1 (da)
DK (1) DK2370441T3 (da)
EC (1) ECSP11011089A (da)
ES (1) ES2431279T3 (da)
HR (1) HRP20131067T1 (da)
IL (1) IL212122A (da)
MA (1) MA32781B1 (da)
MX (1) MX2011005596A (da)
MY (1) MY150837A (da)
NZ (1) NZ592076A (da)
PE (1) PE20110582A1 (da)
PL (1) PL2370441T3 (da)
PT (1) PT2370441E (da)
RU (1) RU2507205C2 (da)
SG (1) SG171846A1 (da)
SI (1) SI2370441T1 (da)
TW (1) TWI379833B (da)
UA (1) UA103504C2 (da)
WO (1) WO2010060836A1 (da)
ZA (1) ZA201103419B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
CA2847095A1 (en) * 2011-10-05 2013-04-11 F. Hoffmann-La Roche Ag Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists
CN105492010B (zh) * 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
HRP20210966T1 (hr) 2013-12-05 2021-09-17 F. Hoffmann - La Roche Ag Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraaza­benzo[e]azulena i njegovih kristalnih oblika
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
MX2020004105A (es) * 2017-12-08 2020-09-22 Hoffmann La Roche Formulacion farmaceutica.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
TR200102069T2 (tr) 1999-01-19 2001-11-21 Ortho-Mcneil Pharmaceutical, Inc. Vasopresin reseptörü antagonistleri olarak trisiklik benzodiazepinler.
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
KR100840852B1 (ko) 2004-05-25 2008-06-23 화이자 프로덕츠 인크. 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
BRPI0514458A (pt) 2004-08-25 2008-06-10 Pfizer triazolbenzodiazepinas e seu uso como antagonistas de vasopressina
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP1885713A1 (en) 2005-05-18 2008-02-13 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
WO2008084005A1 (en) 2007-01-12 2008-07-17 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
WO2009125800A1 (ja) * 2008-04-09 2009-10-15 株式会社クラレ ガスバリア性積層体およびその製造方法
AU2009315754B2 (en) 2008-11-13 2013-08-15 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes
PE20110590A1 (es) 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes

Also Published As

Publication number Publication date
RU2507205C2 (ru) 2014-02-20
CN102227428A (zh) 2011-10-26
US20120225865A1 (en) 2012-09-06
MX2011005596A (es) 2011-06-16
BRPI0922303A2 (pt) 2016-01-12
MY150837A (en) 2014-02-28
JP5452608B2 (ja) 2014-03-26
ZA201103419B (en) 2014-07-30
HK1160642A1 (en) 2012-08-10
SI2370441T1 (sl) 2013-12-31
AU2009319123B2 (en) 2014-10-23
SG171846A1 (en) 2011-07-28
US8227458B2 (en) 2012-07-24
PL2370441T3 (pl) 2014-02-28
UA103504C2 (ru) 2013-10-25
TW201024300A (en) 2010-07-01
HRP20131067T1 (hr) 2013-12-06
CA2743976A1 (en) 2010-06-03
US20100137286A1 (en) 2010-06-03
WO2010060836A1 (en) 2010-06-03
JP2012510441A (ja) 2012-05-10
ECSP11011089A (es) 2011-06-30
RU2011123703A (ru) 2013-01-10
AR074409A1 (es) 2011-01-12
CY1115435T1 (el) 2017-01-04
CA2743976C (en) 2017-02-21
AR112338A2 (es) 2019-10-16
EP2370441A1 (en) 2011-10-05
IL212122A0 (en) 2011-06-30
BRPI0922303B1 (pt) 2019-11-12
KR101359742B1 (ko) 2014-02-06
ES2431279T3 (es) 2013-11-25
PT2370441E (pt) 2013-11-14
CN102227428B (zh) 2015-03-25
MA32781B1 (fr) 2011-11-01
PE20110582A1 (es) 2011-08-17
CO6341478A2 (es) 2011-11-21
NZ592076A (en) 2012-06-29
CR20110220A (es) 2011-06-21
IL212122A (en) 2013-06-27
KR20110077022A (ko) 2011-07-06
AU2009319123A1 (en) 2010-06-03
US8461152B2 (en) 2013-06-11
TWI379833B (en) 2012-12-21
EP2370441B1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DK2374797T3 (da) Benzazepinderivater til anvendelse som vasopressinantagonister
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
DK2129654T3 (da) Antagonister af glucagonreceptoren
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
DK2010498T3 (da) Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK2401269T3 (da) Indolderivater som crth2-receptorantagonister
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
DK2066628T3 (da) 2-Phenylindoler som antagonister af prostaglandin-D2-receptorer
ATE538091T1 (de) Tetrahydrocyclopentaäbüindolverbindungen als androgenrezeptormodulatoren
DK2365754T3 (da) Herbicidsammensætninger indeholdende benzoylpyrazolforbindelser
DK2449057T3 (da) Fremgangsmåde til omdannelse af lignocellulosematerialer til anvendelige kemikalier
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
SI2370441T1 (sl) Arilcikloheksiletri dihidrotetraazabenzoazulenov za uporabo kot antagonisti receptorja vazopresina V1A
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
DK2913326T3 (da) Hidtil ukendte modulatorer af sphingosinphosphatreceptorer